Sildenafil, a Phosphodiesterase Type 5 Inhibitor, Downregulates Osteopontin in Human Peripheral Blood Mononuclear Cells
Tóm tắt
Từ khóa
Tài liệu tham khảo
Afify MF, Mohamed GB, El-Maboud MA et al (2009) Plasma concentration of osteopontin (OPN) in children with systemic lupus erythematosus: relationship with disease activity. Open Autoimmun J 1:59–63
Ashkar S, Weber GF, Panoutsakopoulou V et al (2000) Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287:860–864
Aversa A, Vitale C, Volterrani M et al (2008) Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med 25:37–44
Boswell-Smith V, Spina D, Page CP (2006) Phosphodiesterase inhibitors. Br J Pharmacol 147(suppl 1):S252–S257
Brown A (2012) Osteopontin: a key link between immunity, inflammation and the central nervous system. Transl Neurosci 3:288–293
Cantor H (1995) The role of Eta-1/osteopontin in the pathogenesis of immunological disorders. Ann N Y Acad Sci 760:143–150
Cao DX, Li ZJ, Jiang XO et al (2012) Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol 18:3923–3930
Carecchio M, Comi C (2011) The role of osteopontin in neurodegenerative diseases. J Alzheimers Dis 25:179–185
Chrysant SG, Chrysant GS (2012) The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension. J Clin Hypertens 14:644–649
Clayton RA, Dick CAJ, Mackenzie A et al (2004) The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma. Respir Res 5:4
Denhardt DT, Noda M (1998) Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl 30–31:92–102
Di Luigi L, Corinaldesi C, Colletti M et al (2016) Phosphodiesterase type 5 inhibitor sildenafil decreases the proinflammatory chemokine CXCL10 in human cardiomyocytes and in subjects with diabetic cardiomyopathy. Inflammation 39:1238–1252
Fisher LW, Torchia DA, Fohr B et al (2001) Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 280:460–465
Frenzel DF, Weiss JM (2011) Osteopontin and allergic disease: pathophysiology and implications for diagnostics and therapy. Expert Rev Clin Immunol 7:93–109
Giannetta E, Isidori AM, Galea N et al (2012) Chronic inhibition of cGMP phosphodiesterase 5 A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 125:2323–2333
Giannetta E, Feola T, Gianfrilli D et al (2014) Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med 12:185
Glas J, Seiderer J, Bayrle C et al (2011) The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn’s disease. PLoS One 6:e29309
Harris VK, Sadiq SA (2009) Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther 13:225–244
Jeong KH, Lee TW, Ihm CG et al (2009) Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats. Am J Nephrol 29:274–282
Karakhanova S, Yang Y, Link J et al (2013) Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice. Mol Immunol 56:649–659
Karakhanova S, Link J, Heinrich M et al (2015) Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells. Oncoimmunology 4:e998519
Konno S, Kurokawa M, Uede T et al (2011) Role of osteopontin, a multifunctional protein, in allergy and asthma. Clin Exp Allergy 41:1360–1366
Mishima R, Takeshima F, Sawai T et al (2007) High plasma osteopontin levels in patients with inflammatory bowel disease. J Clin Gastroenterol 41:167–172
Murugaiyan G, Mittal A, Weiner HL (2008) Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 181:7480–7488
New DC, Wong YH (2007) Molecular mechanisms mediating the G protein-coupled receptor regulation of cell cycle progression. J Mol Signal 2:2
Nichols DJ, Muirhead GJ, Harness JA (2002) Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 53(Suppl 1):5S–12S
Nunes AKS, Raposo C, Luna RL et al (2012) Sildenafil (Viagra®) down regulates cytokines and prevents demyelination in a cuprizone-induced MS mouse model. Cytokine 60:540–551
Pifarre P, Prado J, Baltrons MA et al (2011) Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis. Acta Neuropathol 121:499–508
Pifarré P, Gutierrez-Mecinas M, Prado J et al (2014) Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions. Exp Neurol 251:58–71
Ramaiah SK, Rittling S (2008) Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci 103:4–13
Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16:79–87
Schäfer S, Ellinghaus P, Janssen W et al (2009) Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovasc Res 82:30–39
Shinohara ML, Lu L, Bu J et al (2006) Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol 7:498–506
Singh M, Ananthula S, Milhorn DM et al (2007) Osteopontin: a novel inflammatory mediator of cardiovascular disease. Front Biosci 12:214–221
Szczypka M, Ploch S, Obmińska-Mrukowicz B (2012) Modulation of Th1/Th2 cytokine production by selective and nonselective phosphodiesterase inhibitors administered to mice. Pharmacol Rep 64:179–184
Tsai BM, Turrentine MW, Sheridan BC et al (2006) Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Ann Thorac Surg 81:272–278
Uede T (2011) Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases. Pathol Int 61:265–280
Venneri MA, Giannetta E, Panio G et al (2015) Chronic inhibition of PDE5 limits pro-inflammatory monocyte-macrophage polarization in streptozotocin-induced diabetic mice. PLoS One 10:e0126580
Vlachopoulos C, Ioakeimidis N, Rokkas K et al (2015) Acute effect of sildenafil on inflammatory markers/mediators in patients with vasculogenic erectile dysfunction. Int J Cardiol 182:98–101
Wang KX, Denhardt DT (2008) Osteopontin: role in immune regulation and stress response. Cytokine Growth Factor Rev 19:333–345
Yildirim A, Ersoy Y, Ercan F et al (2010) Phosphodiesterase-5 inhibition by sildenafil citrate in a rat model of bleomycin-induced lung fibrosis. Pulm Pharmacol Ther 23:215–221